A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Issue 7 (11th February 2022)

• Record Type: Journal Article
• Authors: Kaplonek, Paulina; Yao, Ling; Reppe, Katrin; Voß, Franziska; Kohler, Thomas; Ebner, Friederike; Schäfer, Alexander; Blohm, Ulrike; Priegue, Patricia; Bräutigam, Maria; Pereira, Claney L.; Parameswarappa, Sharavathi G.; Emmadi, Madhu; Ménová, Petra; Witzenrath, Martin; Hammerschmidt, Sven; Hartmann, Susanne; Sander, Leif E.; Seeberger, Peter H.
• Is Part Of: Vaccine. Volume 40:Issue 7(2022)
• Page Start: 1038
• Page End: 1046
• Publication Date: 2022-02-11
• Subjects: Vaccines -- Carbohydrate vaccines -- Infectious diseases -- Streptococcus pneumoniae -- Carrier protein; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2021.12.068
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Streptococcus pneumoniae (S. pneumoniae) infections are the leading cause of child mortality globally. Current vaccines fail to induce a protective immune response towards a conserved part of the pathogen, resulting in new serotypes causing disease. Therefore, new vaccine strategies are urgently needed. Described is a two-pronged approach combining S. pneumoniae proteins, pneumolysin (Ply) and pneumococcal surface protein A (PspA), with a precisely defined synthetic oligosaccharide, whereby the carrier protein acts as a serotype-independent antigen to provide additional protection. Proof of concept in mice and swine models revealed that the conjugates inhibited colonization of the nasopharynx, decreased the bacterial load and reduced disease severity in the bacteria challenge model. Immunization of piglets provided the first evidence for the immunogenicity and protective potential of synthetic glycoconjugate vaccine in a large animal model. A combination of synthetic oligosaccharides with proteins from the target pathogen opens the path to create broadly cross-protective ("universal") pneumococcal vaccines.